Dr. Yogish Kudva at Mayo Clinic in Rochester, Minnesota Improving outcomes in type 1 diabetes

As a leading researcher in the field of closed-loop therapy, Dr. Kudva is bringing new hope to adults and children with type 1 diabetes.


As a dedicated physician-scientist, Yogish C. Kudva, M.B.B.S., is interested in developing an effective artificial pancreas system to improve outcomes for patients with type 1 diabetes. Dr. Kudva's research also contributes to the creation of new and better cell replacement therapies for patients with type 1 diabetes.

The goal of our research in the Artificial Pancreas Laboratory is to accelerate approval of the closed-loop/artificial endocrine pancreas for treatment of type 1 diabetes. By implementing closed-loop studies, we'll investigate, define, understand and develop physiological models of integrative physiology related to the insulin-glucose system.

A better understanding of the insulin-glucose system as it relates to meals and physical activity and other factors, such as menstrual cycles or sleep cycles, helps inform, develop, refine and validate personalized, state-of-the-art closed-loop artificial pancreas systems to improve the quality of life in people with type 1 diabetes. We are committed to improving existing methods and developing innovative techniques to measure physiological parameters related to these variables.

Our lab's work is supported by a variety of extramural funding, including grants from the National Institute of Diabetes and Digestive and Kidney Diseases. Dr. Kudva also was awarded funding to be part of a consortium to merge physiology, behavior and engineering approaches to optimize closed-loop systems and provide tight glucose control that can be applied in outpatient settings.

About Dr. Kudva

Dr. Kudva is an endocrinologist and a professor of medicine at Mayo Clinic College of Medicine and Science in Rochester, Minnesota. Dr. Kudva's research is advancing treatment options for both adults and children with type 1 diabetes. He is also working to develop stem cell therapy and to improve outcomes for patients undergoing kidney transplant and pancreas transplant.